Recursion Pharmaceuticals is trading at $3.44, up +7.82%, primarily as biotechnology gains 2.55% amid stronger pharmaceutical demand, increased research investment, improved funding conditions, and merger optimism.
- No clear company-specific announcement was identified for September 17, 2026.
- Broader risk appetite is supporting growth stocks, with the Nasdaq Composite up 1.48%.
- Recent conference commentary highlighted clinical progress but predates the current session and does not clearly explain today’s move.